Top

Published in:

01-12-2018 | Original Paper

Induction of apoptosis via proteasome inhibition in leukemia/lymphoma cells by two potent piperidones

Authors: Lisett Contreras, Ruben I. Calderon, Armando Varela-Ramirez, Hong-Yu Zhang, Yuan Quan, Umashankar Das, Jonathan R. Dimmock, Rachid Skouta, Renato J. Aguilera

Published in: Cellular Oncology | Issue 6/2018

Abstract

Purpose

Previously, compounds containing a piperidone structure have been shown to be highly cytotoxic to cancer cells. Recently, we found that the piperidone compound P2 exhibits a potent anti-neoplastic activity against human breast cancer-derived cells. Here, we aimed to evaluate two piperidone compounds, P1 and P2, for their potential anti-neoplastic activity against human leukemia/lymphoma-derived cells.

Methods

Cytotoxicity and apoptosis induction were evaluated using MTS, annexin V-FITC/PI and mitochondrial membrane potential polychromatic assays to confirm the mode of action of the piperidone compounds. The effects of compound P1 and P2 treatment on gene expression were assessed using AmpliSeq analysis and, subsequently, confirmed by RT-qPCR and Western blotting.

Results

We found that the two related piperidone compounds P1 and P2 selectively killed the leukemia/lymphoma cells tested at nanomolar concentrations through induction of the intrinsic apoptotic pathway, as demonstrated by mitochondrial depolarization and caspase-3 activation. AmpliSeq-based transcriptome analyses of the effects of compounds P1 and P2 on HL-60 acute leukemia cells revealed a differential expression of hundreds of genes, 358 of which were found to be affected by both. Additional pathway analyses revealed that a significant number of the common genes were related to the unfolded protein response, implying a possible role of the two compounds in the induction of proteotoxic stress. Subsequent analyses of the transcriptome data revealed that P1 and P2 induced similar gene expression alterations as other well-known proteasome inhibitors. Finally, we found that Noxa, an important mediator of the activity of proteasome inhibitors, was significantly upregulated at both the mRNA and protein levels, indicating a possible role in the cytotoxic mechanism induced by P1 and P2.

Conclusions

Our data indicate that the cytotoxic activity of P1 and P2 on leukemia/lymphoma cells is mediated by proteasome inhibition, leading to activation of pro-apoptotic pathways.

Available only for authorised users

WHO | Cancer WHO Available at: http://www.who.int/mediacentre/factsheets/fs297/en/. (Accessed: 7th November 2017)

WHO Global status report on noncommunicable diseases 2014. WHO Available at: http://www.who.int/nmh/publications/ncd-status-report-2014/en/. (Accessed: 9th November 2017)

American Cancer Society Cancer Facts & Figures 2016. (American Cancer Society, 2016)

X. Ma, H. Yu, Global burden of Cancer. Yale J Biol Med 79, 85–94 (2006)PubMed

D. Hanahan, R.A. Weinberg, Hallmarks of cancer: The next generation. Cell 144, 646–674 (2011)CrossRef

G. M. Cooper, The development and causes of Cancer. in The Cell: A Molecular Approach (Sinauer Associates, 2000)

G. S. Markopoulos, E. Roupakia, M. Tokamani, E. Chavdoula, M. Hatziapostolou, C, Polytarchou, K. B. Marcu, A. G. Papavassiliou, R. Sandaltzopoulos, E. Kolettas, a step-by-step microRNA guide to cancer development and metastasis. Cell Oncol 40, 303–339 (2017)CrossRef

G. M. Cooper, Applications of molecular biology to Cancer prevention and treatment. In The Cell: A Molecular Approach (Sinauer Associates, 2000)

K.L. Nastiuk, J.J. Krolewski, Opportunities and challenges in combination gene cancer therapy. Adv Drug Deliv Rev 98, 35–40 (2016)CrossRef

10.

S. Kummar, H.X. Chen, J. Wright, S. Holbeck, M.D. Millin, J. Tomaszewski, J. Zweibel, J. Collins, J.H. Doroshow, Utilizing targeted cancer therapeutic agents in combination: Novel approaches and urgent requirements. Nat Rev Drug Discov 9, 843–856 (2010)CrossRef

11.

C. Holohan, S.V. Schaeybroeck, D.B. Longley, P.G. Johnston, Cancer drug resistance: An evolving paradigm. Nature Rev Cancer 13, 714–726 (2013)CrossRef

12.

A. Chavez-Gonzalez, B. Bakhshinejad, K. Pakravan, M.L. Guzman, S. Babashah, Novel strategies for targeting leukemia stem cells: Sounding the death knell for blood cancer. Cell Oncol 40, 1–20 (2017)CrossRef

13.

Z. Mousavian, A. Nowzari-Dalini, R.W. Stam, Y. Rahmatallah, A. Masoudi-Nejad, Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia. Cell Oncol 40, 33–45 (2017)CrossRef

14.

Z. Liu, B. Delavan, R. Roberts, W. Tong, Lessons learned from two decades of anticancer drugs. Trends Pharmacol Sciences 38, 852–872 (2017)CrossRef

15.

P. D’Arcy, S. Brnjic, M.H. Olofsson, M. Fryknäs, K. Lindsten, M. De Cesare, P. Perego, B. Sadeghi, M. Hassan, R. Larsson, S. Linder, Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med 17, 1636–1640 (2011)CrossRef

16.

T. Mujtaba, Q.P. Dou, Advances in the understanding of mechanisms and therapeutic use of Bortezomib. Discov Med 12, 471–480 (2011)PubMedPubMedCentral

17.

P. Moreau, P.G. Richardson, M. Cavo, R.Z. Orlowski, J.F.S. Miguel, A. Palumbo, J.-L. Harousseau, Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120, 947–959 (2012)CrossRef

18.

C. Dai, S. Dai, J. Cao, Proteotoxic stress of cancer: Implication of the heat-shock response in oncogenesis. J Cell Physiol 227, 2982–2987 (2012)CrossRef

19.

J. Adams, The proteasome: Structure, function, and role in the cell. Cancer Treatment Rev 29. Supplement 1, 3–9 (2003)CrossRef

20.

T. Hideshima, P.G. Richardson, K.C. Anderson, Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther 10, 2034–2042 (2011)CrossRef

21.

H.-W. Chiu, Y.-C. Tseng, Y.-H. Hsu, Y.-F. Lin, N.-P. Foo, H.-R. Guo, Y.-J. Wang, Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin–proteasome system in human sarcoma cells. Cancer Lett 356, 762–772 (2015)CrossRef

22.

E.A. Obeng, L.M. Carlson, D.M. Gutman, W.J. Harrington, K.P. Lee, L.H. Boise, Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107, 4907–4916 (2006)CrossRef

23.

J.-Z. Qin, J. Ziffra, L. Stennett, B. Bodner, B.K. Bonish, V. Chaturvedi, F. Bennett, P.M. Pollock, J.M. Trent, M.J.C. Hendrix, P. Rizzo, L. Miele, B.J. Nickoloff, Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65, 6282–6293 (2005)CrossRef

24.

M. Baou, S.L. Kohlhaas, M. Butterworth, M. Vogler, D. Dinsdale, R. Walewska, A. Majid, E. Eldering, M.J.S. Dyer, G.M. Cohen, Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica 95, 1510–1518 (2010)CrossRef

25.

D.C.S. Huang, A. Strasser, BH3-only proteins -essential initiators of apoptotic cell death. Cell 103, 839–842 (2000)CrossRef

26.

J.E. Guikema, M. Amiot, E. Eldering, Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer. Expert Opin Ther Targets 21, 767–779 (2017)CrossRef

27.

A.M. Fribley, B. Evenchik, Q. Zeng, B.K. Park, J.Y. Guan, H. Zhang, T.J. Hale, M.S. Soengas, R.J. Kaufman, C.-Y. Wang, Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem 281, 31440–31447 (2006)CrossRef

28.

A. Craxton, M. Butterworth, N. Harper, L. Fairall, J. Schwabe, A. Ciechanover, G.M. Cohen, NOXA, a sensor of proteasome integrity, is degraded by 26S proteasomes by an ubiquitin-independent pathway that is blocked by MCL-1. Cell Death Differ 19, 1424–1434 (2012)CrossRef

29.

L.M. Nunes, M. Hossain, A. Varela-Ramirez, U. Das, Y.M. Ayala-Marin, J.R. Dimmock, R.J. Aguilera, A novel class of piperidones exhibit potent, selective and pro-apoptotic anti-leukemia properties. Oncol Lett 11, 3842–3848 (2016)CrossRef

30.

E. Robles-Escajeda, U. Das, N.M. Ortega, K. Parra, G. Francia, J.R. Dimmock, A. Varela-Ramirez, R.J. Aguilera, A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells. Cell Oncol 39, 265–277 (2016)CrossRef

31.

U. Das, J. Alcorn, A. Shrivastav, R.K. Sharma, E. De Clercq, J. Balzarini, J.R. Dimmock, Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds. Eur J Med Chem 42, 71–80 (2007)CrossRef

32.

E. Robles-Escajeda, D. Lerma, A.M. Nyakeriga, J.A. Ross, R.A. Kirken, R.J. Aguilera, A. Varela-Ramirez, Searching in mother nature for anti-cancer activity: Anti-proliferative and pro-apoptotic effect elicited by green barley on leukemia/lymphoma cells. PLoS One 8, e73508 (2013)CrossRef

33.

Y. Quan, B. Li, Y.-M. Sun, H.-Y. Zhang, Elucidating pharmacological mechanisms of natural medicines by biclustering analysis of the gene expression profile: A case study on curcumin and si-wu-tang. Int J Mol Sci 16, 510–520 (2014)CrossRef

34.

K. Segawa, S. Nagata, An apoptotic ‘eat me’ signal: Phosphatidylserine exposure. Trends Cell Biol 25, 639–650 (2015)CrossRef

35.

S.W.G. Tait, D.R. Green, Mitochondria and cell death: Outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11, 621–632 (2010)CrossRef

36.

A.L. Davis, S. Qiao, J.L. Lesson, M. Rojo de la Vega, S.L. Park, C.M. Seanez, V. Gokhale, C.M. Cabello, G.T. Wondrak, The quinone methide Aurin is a heat shock response inducer that causes proteotoxic stress and Noxa-dependent apoptosis in malignant melanoma cells. J Biol Chem 290, 1623–1638 (2015)CrossRef

37.

X.H. Lowman, M.A. McDonnell, A. Kosloske, O.A. Odumade, C. Jenness, C.B. Karim, R. Jemmerson, A. Kelekar, The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose. Mol Cell 40, 823–833 (2010)CrossRef

38.

I.N. Mungrue, J. Pagnon, O. Kohannim, P.S. Gargalovic, A.J. Lusis, CHAC1/MGC4504 is a novel proapoptotic component of the unfolded protein response, downstream of the ATF4-ATF3-CHOP cascade. J Immunol 182, 466–476 (2009)CrossRef

39.

C.V. Dang, C-Myc target genes involved in cell growth, apoptosis. and metabolism Mol Cell Biol 19, 1–11 (1999)CrossRef

40.

J. Wang, L.Y. Xie, S. Allan, D. Beach, G.J. Hannon, Myc activates telomerase. Genes Dev 12, 1769–1774 (1998)CrossRef

41.

B.-J. Chen, Y.-L. Wu, Y. Tanaka, W. Zhang, Small molecules targeting c-Myc oncogene: Promising anti-cancer therapeutics. Int J Biol Sci 10, 1084–1096 (2014)CrossRef

42.

J. Lamb, E.D. Crawford, D. Peck, J.W. Modell, I.C. Blat, M.J. Wrobel, J. Lerner, J.-P. Brunet, A. Subramanian, K.N. Ross, M. Reich, H. Hieronymus, G. Wei, S.A. Armstrong, P.A. Clemons, R. Wei, S.A. Carr, E.S. Lander, T.R. Golub, The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929–1935 (2006)CrossRef

43.

G. de Bettignies, O. Coux, Proteasome inhibitors: Dozens of molecules and still counting. Biochimie 92, 1530–1545 (2010)CrossRef

44.

H. Mi, X. Huang, A. Muruganujan, H. Tang, C. Mills, D. Kang, P.D. Thomas, PANTHER version 11: Expanded annotation data from gene ontology and Reactome pathways, and data analysis tool enhancements. Nucleic Acids Res 45, D183–D189 (2017)CrossRef

45.

C. Ploner, R. Kofler, A. Villunger, Noxa: At the tip of the balance between life and death. Oncogene 27, S84–S92 (2009)CrossRef

46.

N. Guo, Z. Peng, MG132, a proteasome inhibitor, induces apoptosis in tumor cells. Asia-Pacific J Clin Oncol 9, 6–11 (2013)CrossRef

47.

L. Galluzzi, M.C. Maiuri, I. Vitale, H. Zischka, M. Castedo, L. Zitvogel, G. Kroemer, Cell death modalities: Classification and pathophysiological implications. Cell Death Differ 14, 1237–1243 (2007)CrossRef

48.

N. Mohana-Kumaran, D.S. Hill, J.D. Allen, N.K. Haass, Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy. Pigment Cell Melanoma Res 27, 525–539 (2014)CrossRef

49.

S. Elmore, Apoptosis: A review of programmed cell death. Toxicol Pathol 35, 495–516 (2007)CrossRef

50.

W. Li, A. Turner, P. Aggarwal, A. Matter, E. Storvick, D.K. Arnett, U. Broeckel, Comprehensive evaluation of AmpliSeq transcriptome, a novel targeted whole transcriptome RNA sequencing methodology for global gene expression analysis. BMC Genomics 16, 1069 (2015)CrossRef

51.

S.L. Downey, B.I. Florea, H.S. Overkleeft, A.F. Kisselev, Use of proteasome inhibitors. Curr Protoc Immunol 109, 9.10.1–9.10.8 (2015)CrossRef

52.

M.A. Nikiforov, M. Riblett, W.-H. Tang, V. Gratchouck, D. Zhuang, Y. Fernandez, M. Verhaegen, S. Varambally, A.M. Chinnaiyan, A.J. Jakubowiak, M.S. Soengas, Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci U S A 104, 19488–19493 (2007)CrossRef

53.

C. Hetz, E. Chevet, H.P. Harding, Targeting the unfolded protein response in disease. Nat Rev Drug Discov 12, 703–719 (2013)CrossRef

54.

M. Edagawa, J. Kawauchi, M. Hirata, H. Goshima, M. Inoue, T. Okamoto, A. Murakami, Y. Maehara, S. Kitajima, Role of activating transcription factor 3 (atf3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through up-regulation of death receptor 5 (DR5) by zerumbone and celecoxib. J Biol Chem 289, 21544–21561 (2014)CrossRef

55.

I.B. Roninson, Oncogenic functions of tumour suppressor p21Waf1/Cip1/Sdi1: Association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 179, 1–14 (2002)CrossRef

56.

X.E. Guo, B. Ngo, A.S. Modrek, W.-H. Lee, Targeting tumor suppressor networks for Cancer therapeutics. Curr Drug Targets 15, 2–16 (2014)CrossRef

57.

X. Wang, M. Mazurkiewicz, E.-K. Hillert, M.H. Olofsson, S. Pierrou, P. Hillertz, J. Gullbo, K. Selvaraju, A. Paulus, S. Akhtar, F. Bossler, A.C. Khan, S. Linder, P.D. Arcy, The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells. Sci Rep 6, srep26979 (2016)CrossRef

58.

P. D’Arcy, X. Wang, S. Linder, Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacol Ther 147, 32–54 (2015)CrossRef

59.

A. Varela-Ramirez, Female versus male cells in anti-Cancer drug discovery: The winner is …. AAPS Blog (2014) Available at: https://aapsblog.aaps.org/2014/06/18/female-versus-male-cells-in-anti-cancer-drug-discovery-the-winner-is/

60.

L.M. Nunes, E. Robles-Escajeda, Y. Santiago-Vazquez, N.M. Ortega, C. Lema, A. Muro, G. Almodovar, U. Das, S. Das, J.R. Dimmock, R.J. Aguilera, A. Varela-Ramirez, The gender of cell lines matters when screening for novel anti-cancer drugs. AAPS J 16, 872–874 (2014)CrossRef

61.

Y. Santiago-Vázquez, U. Das, A. Varela-Ramirez, S.T. Baca, Y. Ayala-Marin, C. Lema, S. Das, A. Baryyan, J.R. Dimmock, R.J. Aguilera, Tumor-selective cytotoxicity of a novel pentadiene analogue on human leukemia/ lymphoma cells. Clin Cancer Drugs 3, 138–146 (2016)CrossRef

62.

J.A. Clayton, F.S. Collins, NIH to balance sex in cell and animal studies. Nature 509, 282–283 (2014)CrossRef

63.

E. Pollitzer, Cell sex matters. Nature 500, 23–24 (2013)CrossRef

Title: Induction of apoptosis via proteasome inhibition in leukemia/lymphoma cells by two potent piperidones
Authors: Lisett Contreras
Ruben I. Calderon
Armando Varela-Ramirez
Hong-Yu Zhang
Yuan Quan
Umashankar Das
Jonathan R. Dimmock
Rachid Skouta
Renato J. Aguilera
Publication date: 01-12-2018
Publisher: Springer Netherlands
Published in: Cellular Oncology / Issue 6/2018
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-018-0397-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma

The emerging role of lncRNAs in the regulation of cancer stem cells

Epigenetic markers in basal cell carcinoma: universal themes in oncogenesis and tumor stratification? - a short report

In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells

CXCL12 expression is a bona fide predictor of recurrence in lung neuroendocrine tumours; a multicentric study with emphasis on atypical carcinoids - a short report

Metformin inhibits human breast cancer cell growth by promoting apoptosis via a ROS-independent pathway involving mitochondrial dysfunction: pivotal role of superoxide dismutase (SOD)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer